68 related articles for article (PubMed ID: 20102407)
1. HER-2/neu receptor gene status in endometrial carcinomas: a tissue microarray study.
Xu M; Schwartz P; Rutherford T; Azodi M; Santin A; Silasi D; Martel M; Hui P
Histopathology; 2010 Jan; 56(2):269-73. PubMed ID: 20102407
[No Abstract] [Full Text] [Related]
2. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
3. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
Williams JA; Wang ZR; Parrish RS; Hazlett LJ; Smith ST; Young SR
Exp Mol Pathol; 1999 Dec; 67(3):135-43. PubMed ID: 10600396
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium.
Rasty G; Murray R; Lu L; Kubilis P; Benrubi G; Masood S
Ann Clin Lab Sci; 1998; 28(3):138-43. PubMed ID: 9646853
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
7. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium.
Brys M; Semczuk A; Rechberger T; Krajewska WM
Oncol Rep; 2007 Jul; 18(1):261-5. PubMed ID: 17549377
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
Kohlberger P; Loesch A; Koelbl H; Breitenecker G; Kainz C; Gitsch G
Cancer Lett; 1996 Jan; 98(2):151-5. PubMed ID: 8556702
[TBL] [Abstract][Full Text] [Related]
10. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
13. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
14. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
15. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
16. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.
Bigsby RM; Li AX; Bomalaski J; Stehman FB; Look KY; Sutton GP
Obstet Gynecol; 1992 Jan; 79(1):95-100. PubMed ID: 1345772
[TBL] [Abstract][Full Text] [Related]
19. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
Huang WY; Newman B; Millikan RC; Conway K; Hulka BS; Schell MJ; Liu ET
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):65-71. PubMed ID: 10667465
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
Anttinen J; Kuopio T; Nykanen M; Torkkeli H; Saari U; Juhola M
Anticancer Res; 2003; 23(5b):4213-8. PubMed ID: 14666627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
